{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.30","upperLimit":"71.11","value":"58.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"IND I: Pts receive cytarabine IT \\& ADE as in Arm A, IND I \\& sorafenib tosylate PO days 11-28.\n\nIND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.\n\nINT I: Pts receive cytarabine IT \\& AE as in Arm A, INT II, \\& sorafenib tosylate PO daily days 6-28.\n\nINT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), \\& sorafenib tosylate PO days 7-34.\n\nSCT (HR patients with matched family \\[MFD\\] or unrelated donor):\n\nPts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.\n\nPts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.","id":"OG000","title":"Arm C (Cohort 3)"}],"paramType":"NUMBER","populationDescription":"Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"EFS for Patients on Arm C, Cohort 3","type":"PRIMARY","unitOfMeasure":"percentage of patients"}